Oncolytic Virus (oHSV)

Pipeline

Developing Products That are
Potent, Enabling, Novel and Safe

Oncolytic Virus (oHSV) Pipeline

Product Indication Drug Discovery Pre-clinical IND Phase I Phase II Phase III BLA Commer-cialization: MVR-T3011 IP

MVR-T3011 IP

MVR-T3011 IP

MVR-T3011 IP Combo PD-1

MVR-T3011 IT

MVR-T3011 IT Combo PD-1

MVR-T3011 IT

MVR-T3011 IV

MVR-C5252

Bladder Cancer, BCG-unresponsive NMIBC (Papillary and CIS)

Bladder Cancer, BCG-unresponsive NMIBC (Papillary and CIS)

Bladder Cancer, BCG-naive NMIBC (Papillary and CIS)

Bladder Cancer, MIBC

HNSCC and other Solid Tumors

HNSCC and other Solid Tumors

HNSCC and other Solid Tumors

Solid Tumors

Glioma

FDA (Global MRCT), Phase ll (NCT06971614)

NMPA, Phase I/IIT (NCT06427291)¹

NMPA, IIT

NMPA, IIT

FDA, Phase I/lla (NCT04370587), Fast Track Designation²

FDA, Phase I/lla (NCT04370587)

NMPA, Phase I/lla (NCT05602792)

FDA, Phase I/IIa (NCT04780217）

FDA, Phase I/IIT (NCT06126744), Orphan Drug Designation³

Note:

(1) This is a Phase I dose escalation and expansion investigator-initiated trial (IIT) of MVR-T3011 as a monotherapy administered intravesically in patients with high-risk, BCG-failure (including BCG-unresponsive and BCG-intolerant) NMIBC in China.

(2) The intratumoral MVR-T3011 was granted the Fast Track Designation by the FDA in March 2024 for the treatment of recurrent or metastatic HNSCC patients who failed platinum-containing chemotherapy and anti-PD-(L)1 therapy.

(3) MVR-C5252 was granted the Orphan Drug Designation (ODD) by the FDA for the treatment of malignant glioma in August 2022.

Various Administration Methods

Intravenous

Intratumoral

Intraperitoneal,

intrapleural,

intravesical

Multi-regional Clinical Trials

Clinical trials are the research studies intended to find out if a new treatment is safe and provides better outcomes than the existing standard of care–the best available known treatment. You can find more information about our ongoing clinical trials below.

01

MVR-T3011 IP Global MRCT (NCT06971614)

ll clinical study to evaluate the efficacy and safety of intravesical T3011 injection in participants with BCG-unresponsive high-risk NMlBC or BCG-exposed, chemotherapy-unresponsive intermediate / high-risk NMIBC.
02

MVR-T3011 IT US(NCT04370587）

A Phase 1/2a , open-label study to evaluate the safety and preliminary efficacy of intratumoral T3011 given alone and in combination with intravenous pembrolizumab in patients with advanced or metastatic solid tumors.
03

MVR-C5252 US

A Clinical Study of Intratumoral MVR-C5252 (C5252) in Patients With Recurrent or Progressive Glioblastoma

Biomarker

Biomarker kit to assess the efficacy of OV products and pre-screen potential patients for oHSV clinical treatment

Platform Product R&D/Pilot test/Manufacturing Drug Quality Control Clinical Trials Registration Approval: Biomarker Program

Biomarker Kit

A company focusing on developing novel

drug delivery vector technology

Phone:0512-66202028

Address:Wuzhong Biology Medical Company Industrial Park Phase 3 Block A2, Guoxiang Street, Wuzhong District, Suzhou, China

Private Policy